

117TH CONGRESS  
1ST SESSION

# H. R. 173

To amend the Public Health Service Act to authorize the Secretary to make grants and enter into cooperative agreements with entities to expand and support activities with respect to the prevention and treatment of a covered condition, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

JANUARY 4, 2021

Ms. VELÁZQUEZ (for herself, Ms. DEAN, Mr. NADLER, Mr. SEAN PATRICK MALONEY of New York, Ms. MENG, and Mr. Sires) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend the Public Health Service Act to authorize the Secretary to make grants and enter into cooperative agreements with entities to expand and support activities with respect to the prevention and treatment of a covered condition, and for other purposes.

1       *Be it enacted by the Senate and House of Representa-  
2       tives of the United States of America in Congress assembled,*

3       **SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “COVID–19 Prevention  
5       and Awareness Act of 2021”.

1   **SEC. 2. COVID-19 PREVENTION AND AWARENESS GRANTS.**

2       Subpart I of part D of title III of the Public Health  
3   Service Act (42 U.S.C. 254b et seq.) is amended by adding  
4   at the end the following:

5   **“SEC. 330N. PROGRAM TO PREVENT AND TREAT COVERED  
6                    CONDITIONS.**

7       “(a) IN GENERAL.—The Secretary, acting through  
8   the Director of the Centers for Disease Control and Pre-  
9   vention, may award grants and enter into cooperative  
10   agreements with covered entities to expand and support  
11   activities with respect to the prevention and treatment of  
12   covered conditions, including—

13       “(1) conducting screenings, surveillance, and di-  
14   agnostic testing for covered conditions;

15       “(2) providing guidance to individuals on such  
16   prevention and treatment activities; and

17       “(3) providing guidance on vaccinations rec-  
18   ommended by the Advisory Committee on Immuniza-  
19   tion Practices established by the Secretary.

20       “(b) APPLICATION.—An entity seeking a grant under  
21   this section shall submit an application to the Secretary  
22   at such time, in such manner, and accompanied by such  
23   information as the Secretary may require.

24       “(c) PRIORITY.—In awarding grants or entering into  
25   cooperative agreements under this section, the Secretary  
26   shall give priority to—

1           “(1) federally qualified health centers (as de-  
2       fined in section 330A);

3           “(2) community-based organizations; and

4           “(3) entities that have an agreement with a fed-  
5       erally-qualified health center.

6       “(d) REPORTS.—

7           “(1) REPORT TO SECRETARY.—An entity that  
8       receives a grant or enters into a cooperative agree-  
9       ment under this section shall submit to the Sec-  
10      retary a report that includes—

11           “(A) a description of each activity carried  
12      out—

13           “(i) pursuant to the cooperative  
14      agreement; or

15           “(ii) with amounts received through  
16      the grant; and

17           “(B) an evaluation of the effectiveness of  
18      each such activity.

19           “(2) REPORT TO CONGRESS.—Not later than 3  
20      years after the date of the enactment of this section,  
21      the Secretary shall submit to Congress a report on  
22      the effectiveness of the grants and cooperative agree-  
23      ments entered into under this section.

24           “(e) SUPPLEMENT NOT SUPPLANT.—An entity re-  
25      ceiving a grant under this section shall use grant amounts

1 to supplement, not supplant, any other Federal, State, and  
2 local funds that would otherwise be expended by such enti-  
3 ty to carry out the activities described in this section.

4       “(f) DEFINITIONS.—In this section:

5           “(1) COVERED CONDITION.—The term ‘covered  
6 condition’ means a disease or condition that has  
7 been identified by the Centers for Disease Control  
8 and Prevention to increase, or likely increase, the  
9 risk of mortality from COVID–19 or to increase, or  
10 likely increase, the risk of severe illness from  
11 COVID–19, including the following:

12           “(A) Asthma.

13           “(B) Cancer.

14           “(C) Cerebrovascular disease.

15           “(D) Chronic kidney disease.

16           “(E) Chronic obstructive pulmonary dis-  
17 ease.

18           “(F) Cystic fibrosis.

19           “(G) Hypertension or high blood pressure.

20           “(H) Liver disease.

21           “(I) Neurologic conditions, including de-  
22 mentia.

23           “(J) Obesity.

24           “(K) Pregnancy.

25           “(L) Pulmonary fibrosis.

1           “(M) Serious heart conditions, including  
2           heart failure, coronary artery disease, and car-  
3           diomyopathy.

4           “(N) Sickle cell disease.

5           “(O) Pulmonary conditions resulting from  
6           tobacco use.

7           “(P) Thalassemia.

8           “(Q) Tobacco use.

9           “(R) Type 1 and 2 diabetes mellitus.

10          “(S) Weakened immune system, including  
11          from—

12           “(i) a solid organ transplant;

13           “(ii) a blood or bone marrow trans-  
14          plant;

15           “(iii) the human immunodeficiency  
16          virus; and

17           “(iv) the use of a corticosteroid or  
18          other immune weakening medicine.

19          “(2) COVERED ENTITY.—The term ‘covered en-  
20          tity’ includes the following:

21           “(A) Federally qualified health center (as  
22          defined in section 330A).

23           “(B) Entity that has an agreement with a  
24          federally qualified health center.

25           “(C) Community-based organization.

1                   “(D) Faith-based organization.

2                   “(E) Nonprofit organization.

3       “(g) AUTHORIZATION OF APPROPRIATIONS.—To  
4 carry out this section, there is authorized to be appro-  
5 priated \$2,000,000,000 for the period of fiscal years 2021  
6 through 2022, to remain available until expended.

**7 "SEC. 330O. GRANT PROGRAM TO INCREASE AWARENESS**

**8                   OF THE RELATIONSHIP BETWEEN COVERED**

**9                   CONDITIONS AND COVID-19.**

10        "(a) IN GENERAL.—The Secretary, acting through  
11 the Director of the Centers for Disease Control and Pre-  
12 vention, may award grants to entities to carry out a cam-  
13 paign to increase awareness of the relationship between—

14                   “(1) covered conditions; and

“(2) the increased risk of developing a severe illness or mortality from COVID-19.

17        “(b) APPLICATION.—An entity seeking a grant under  
18 this section shall submit an application to the Secretary  
19 at such time, in such manner, and accompanied by such  
20 information as the Secretary may require, including a de-  
21 scription of how the entity intends to carry out the activi-  
22 ties specified in subsection (c).

23        "(c) CAMPAIGN ACTIVITIES.—In carrying out the  
24 campaign under subsection (a), an entity shall—

1           “(1) develop and disseminate informational ma-  
2       terial—

3           “(A) that is culturally and linguistically  
4       appropriate;

5           “(B) targeted toward communities and  
6       populations that are at a high risk of—

7           “(i) developing a covered condition;  
8       and

9           “(ii) contracting COVID–19;

10          “(C) that increases awareness of the safety  
11       and effectiveness of a COVID–19 vaccine; and

12          “(D) that identifies locations in the com-  
13       munity served by the entity where COVID–19  
14       vaccines are administered;

15          “(2) consult with members of such communities  
16       and populations to develop the informational mate-  
17       rial under paragraph (1); and

18          “(3) disseminate informational material on  
19       treatments available for covered conditions, includ-  
20       ing, if applicable, treatments provided by the entity.

21          “(d) PRIORITY.—In awarding grants under this sec-  
22       tion, the Secretary shall give priority to—

23           “(1) federally qualified health centers (as de-  
24       fined in section 330A);

25           “(2) community-based organizations; and

1               “(3) entities that have an agreement with a fed-  
2 erally qualified health center.

3               “(e) REPORTS.—

4               “(1) REPORT TO SECRETARY.—An entity that  
5 receives a grant under this section shall submit to  
6 the Secretary a report that includes—

7                       “(A) a description of each activity carried  
8 out with amounts received through the grant;  
9 and

10               “(B) an evaluation of the effectiveness of  
11 each such activity.

12               “(2) REPORT TO CONGRESS.—Not later than 3  
13 years after the date of the enactment of this section,  
14 the Secretary shall submit to Congress a report on  
15 the effectiveness of the grants entered into under  
16 this section.

17               “(f) SUPPLEMENT NOT SUPPLANT.—An entity re-  
18 ceiving a grant under this section shall use grant amounts  
19 to supplement, not supplant, any other Federal, State, and  
20 local funds that would otherwise be expended by such enti-  
21 ty to carry out the activities described in this section.

22               “(g) DEFINITIONS.—In this section:

23                       “(1) COVERED CONDITION.—The term ‘covered  
24 condition’ has the meaning given such term in sec-  
25 tion 330N.

1           “(2) COVID–19 VACCINE.—The term ‘COVID–  
2       19 vaccine’ means a vaccine that is intended to pre–  
3       vent, mitigate, or treat the virus that causes  
4       COVID–19 and—

5           “(A) is licensed under section 351 of the  
6       Public Health Service Act (42 U.S.C. 262); or

7           “(B) authorized under section 564 of the  
8       Federal Food, Drug, and Cosmetic Act (21  
9       U.S.C. 360bbb–3).

10          “(h) AUTHORIZATION OF APPROPRIATIONS.—To  
11       carry out this section, there is authorized to be appro–  
12       priated \$120,000,000 for the period of fiscal years 2021  
13       through 2022, to remain available until expended.”.

